If you could vote on Brexit now which option would you choose?
   

TGA provisionally approves COVID-19 vaccine, Nuvaxovid, for use in 12-17 year olds


Australia’s Therapeutic Goods Administration (TGA) has provisionally approved the Biocelect - on behalf of US biotech Novavax (Nasdaq: NVAX) - COVID-19 vaccine, Nuvaxovid, for use in individuals aged 12-17 years. The decision follows provisional approvals on 19 January 2022 for the use of Nuvaxovid in adults, on June 9, 2022, the Nuvaxovid booster dose for use in adults. As with adults, the vaccine should be administered in adolescents intramuscularly…

The Pharma Letter - July 25, 2022

View the full story here: https://www.thepharmaletter.com/article/tga-provisionally-approves-covid-19-vaccine-nuvaxovid-for-use-in-12-17-year-olds